Spring naar hoofd-inhoud

Diopsys® NOVA™  Vision Testing System

For several years now, tremendous progress has been made in glaucoma management and medical retina through Diopsys® NOVA™  Vision Testing System.

Making electrophysiologic testing accessible and efficient in the clinic.

Electrophysiologic testing is usually associated with a time-consuming and uncomfortable test in which the graphs are difficult to interpret. Therefore testing has been performed almost exclusively by universities for decades.

However, Diopsys has developed highly conductive skin electrodes that allow simple and fast testing without any discomfort or corneal risk for the patient. In addition, a normative database has been established and qualitative parameters for the obtained curve were developed in order to  make interpretation of the result very easy for the clinician.


Where visual field testing and OCT provide a report on the cumulative functional resp. structural damage that has  developed over the years, the analysis with Diopsys' pattern ERG (pERG) provides an immediate picture of current disease activity. This saves a lot of time as you no longer need waiting months or years to detect further progression on visual field testing or OCT.

Obtaining Diopsys’ pERG will help you guide glaucoma management in a very wide range of clinical situations, such as:

  • To find out if the current level of  IOP is causing ganglion cell damage
  • Verify whether the obtained IOP reduction after treatment is sufficient
  • Determine whether an occludable anterior chamber angle (PACS) requires treatment
  • Verify whether the treatment of an occludable anterior chamber angle (PACS) has given a satisfactory result
  • Distinguish normals from preperimetric glaucoma cases in patients with a suspicious optic disc without convincing visual field and / or OCT results.
  • Distinguish normals from glaucoma cases in patients with varying or unreliable performance of visual field tests
  • Detection of persistent ganglion cell dysfunction in existing visual field defects despite obtaining (apparently) sufficient IOP reduction.
  • Evaluation of complaints of poor visual quality

The implementation of Diopsys' pERG makes it possible to obtain an analysis of the current ganglion cell function for all degrees of visual field defects. Normalisation of ganglion cell function is obtained within 3 months of elimination of the mechanism of damage. This allows you to assess the actual ganglion cell function and permits to verify if the treatment is producing sufficient results in a very short time frame.

Via this link you can watch a video in which Mark Latina (Tufts university school of medicine) gives an introduction to Diopsys' pERG technology.
This link will take you to the Diopsys website, where you will find more information about the applications of Diopsys® NOVA™  Vision Testing System in the field of glaucoma management and medical retina.

If you wish to contact cVision, distributor of Diopsys® NOVA™  Vision Testing System in Belgium, send us an email : sales@cvision.be

Medical retina

Visual activity provides us of a measure of central foveal function in a 100% contrast setting. However this measure is subjective and even when half of the fovea is obscured or non-functioning, patients may still achieve 10/10 vision. Visual field testing is another way to measure visual function but requires patient coöperation and may suffer considerable inter-test variability.

The full field flicker ERG (ffERG) is a light  induced visual response and the only diagnostic test that allows the clinician to obtain an objective assessment of photoreceptor function. It has evolved from the earlier time-domain to a frequency domain analysis, using a flash stimulus of a frequency higher than the refresh rate of rod photoreceptors, measuring cone function. Although cone density is highest in the fovea, the fovea contains only 3.3% of all cones that are distributed throughout the retina. ffERG measures the stimulation of the entire retina, providing a measure of global retinal function. It serves as a biomarker to demonstrate functional changes independent of structural tests (OCT) and can detect loss of function before structural changes are detectable.

Detecting diseased (but still viable) cells allows for intervention aiming for functional recovery and allows you to evaluate the impact of treatment.

ffERG is easy to use, non-invasive, fast and gives a standard report that is very simple to interpret: equally spaced high peaks on the magnitude graphs and closely packed lines pointing in around 5 o’clock in the lower right quadrant of the Mag/Phase plot indicate good cone function. ffERG results are reliable even when media opacities are present.